BioCentury
ARTICLE | Company News

China's 3SBio in-licenses second PharmAbcine mAb

January 16, 2015 3:50 AM UTC

PharmAbcine Inc. (Daejon, South Korea) granted 3SBio Inc. (Shenyang, China) an exclusive license to develop DIG-KT ( TRPH 011) in greater China and Korea. The bispecific antibody against vascular endothelial growth factor (VEGF) receptor 2 ( KDR/Flk-1; VEGFR-2) and tyrosine kinase receptor 2 ( Tie2) is in preclinical development for solid tumors.

PharmAbcine will receive an undisclosed upfront payment and is eligible for milestones and royalties. 3SBio said it plans to conduct clinical trials in both China and Korea of the human bispecific antibody, but did not give a timeline. ...